However, patients with BRCA/PALB2 variants were associated with the expression of biomarkers that are potentially associated with response to immunotherapy such as tumor mutation burden (TMB), PD‐L1 expression, and microsatellite instability (MSI) status (Seeber et al., 2020). This evidence concerns the gene CD274 and neoplasm.